Certolizumab pegol
| Monoclonal antibody | |
|---|---|
| Type | Fab' fragment |
| Source | Humanized (from mouse) |
| Target | TNF alpha |
| Clinical data | |
| Trade names | Cimzia |
| AHFS/Drugs.com | Consumer Drug Information |
| MedlinePlus | a608041 |
| Pregnancy category |
|
| Routes of administration |
Subcutaneous |
| ATC code | L04AB05 (WHO) |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Biological half-life | about 11 days |
| Excretion | Renal (PEG only) |
| Identifiers | |
| CAS Number |
428863-50-7 
|
| ChemSpider | none |
| UNII |
UMD07X179E
|
| KEGG |
D03441 
|
| ChEMBL |
CHEMBL1201831
|
| Chemical and physical data | |
| Formula | C2115H3252N556O673S16 |
| Molar mass | 47,750 g/mol |
|
(what is this?)
|
|
Certolizumab pegol (CDP870, tradename Cimzia) is a biologic medication for the treatment of Crohn's disease,rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. It is a fragment of a monoclonal antibody specific to tumor necrosis factor alpha (TNF-α) and is manufactured by UCB.
Certolizumab pegol is a monoclonal antibody directed against tumor necrosis factor alpha. More precisely, it is a PEGylated Fab' fragment of a humanized TNF inhibitor monoclonal antibody.
Significant side effects occur in 2% of people who take the medication.
...
Wikipedia